Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prosta
 

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

More...